Literature DB >> 11390699

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

S Welkos1, S Little, A Friedlander, D Fritz, P Fellows.   

Abstract

Vaccines which are efficacious against anthrax, such as the human vaccine, Anthrax Vaccine Absorbed (AVA), contain the protective antigen (PA) component of the anthrax toxins as the major protective immunogen. Although AVA protects against inhalational anthrax, the immune responses to and role in protection of PA and possibly other antigens have yet to be fully elucidated. Sera from animals immunized with a toxin-producing, unencapsulated live vaccine strain of Bacillus anthracis have been reported to have anti-spore activities associated with the antitoxin humoral response. The authors performed studies to determine whether anti-PA antibody (Ab)-containing preparations stimulated spore uptake by phagocytes and suppressed the germination of spores in vitro. AVA- and PA-immune sera from several species enhanced the phagocytosis by murine peritoneal macrophages of spores of the virulent Ames and the Sterne vaccine strains. Antitoxin Abs appeared to contribute significantly, although not solely, to the enhanced uptake. Rabbit antisera to PA purified from either Sterne or a PA-producing pX01-cured recombinant, affinity-purified anti-PA IgG, and monkey antisera to AVA were used to assess the role of anti-PA ABS: Rabbit anti-PA Abs promoted the uptake of spores of the PA-producing strains Sterne, Ames and RP42, a mutant of Sterne producing only PA, but not of the pX01-Sterne-1 strain, Ames strain, or RP4, a mutant of Sterne with deletions in the loci encoding PA and the oedema factor (EF) toxin component and producing only the lethal factor toxin component. Rabbit anti-PA and monkey anti-AVA Abs also significantly inhibited spore germination in vitro compared to preimmune serum or medium. Spore-associated proteins recognized by anti-PA Abs were detected by electron microscopy and confirmed by immunoblotting of spore coat extracts. Thus, the anti-PA Ab-specific immunity induced by AVA has anti-spore activity and might have a role in impeding the early stages of infection with B. anthracis spores.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390699     DOI: 10.1099/00221287-147-6-1677

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  91 in total

1.  Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities.

Authors:  Tod J Merkel; Pin-Yu Perera; Vanessa K Kelly; Anita Verma; Zara N Llewellyn; Thomas A Waldmann; Joseph D Mosca; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 3.  Development of an improved vaccine for anthrax.

Authors:  Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

5.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

6.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

7.  Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.

Authors:  Indira T Kudva; Robert W Griffin; Jeonifer M Garren; Stephen B Calderwood; Manohar John
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

8.  Deterministic models of inhalational anthrax in New Zealand white rabbits.

Authors:  Bradford Gutting
Journal:  Biosecur Bioterror       Date:  2014-02-14

9.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

10.  Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay.

Authors:  R E Biagini; D L Sammons; J P Smith; E H Page; J E Snawder; C A F Striley; B A MacKenzie
Journal:  Occup Environ Med       Date:  2004-08       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.